Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kodiak SciencesMEX:KOD 27 OCF Yield % is -5.71 as of Jul. 14, 2026. GuruFocus rates MEX:KOD with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 1,410 Biotechnology companies, Kodiak Sciences ranks better than 56.81% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Kodiak Sciences OCF Yield % Related Terms
Kodiak Sciences OCF Yield % Historical Data
* Premium members only.
The historical data trend for Kodiak Sciences's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:KOD vs ABCL, AGIO, IMNM: OCF Yield % Comparison
For the Biotechnology subindustry, Kodiak Sciences's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kodiak Sciences OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kodiak Sciences's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Kodiak Sciences's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kodiak Sciences (MEX:KOD) has a OCF Yield % of -5.71 as of Jul. 14, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Kodiak Sciences and its competitors. According to the industry distribution chart, Kodiak Sciences ranks #609 out of 1410 companies in the Biotechnology industry, placing it in the top 43.2%.
Is Kodiak Sciences' OCF Yield % too high?
Kodiak Sciences' current OCF Yield % is -5.71. Based on the distribution chart, Kodiak Sciences ranks #609 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Kodiak Sciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Kodiak Sciences' OCF Yield % compare to ABCL and AGIO?
According to the Biotechnology industry distribution chart, Kodiak Sciences ranks #609 out of 1410 companies for OCF Yield %. This puts Kodiak Sciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Kodiak Sciences and its competitors. Kodiak Sciences's current OCF Yield % is -5.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kodiak Sciences stock overvalued right now?
Kodiak Sciences (MEX:KOD) has a current OCF Yield % of -5.71. The current OCF Yield % is -5.71. Kodiak Sciences' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Kodiak Sciences (MEX:KOD), the current OCF Yield % is -5.71 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
27GF Score
Get the complete analysis for MEX:KOD
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:KOD has been successfully added to your 
